Blue Trust Inc. Boosts Stock Position in Bruker Corporation $BRKR

Blue Trust Inc. boosted its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 63.1% in the second quarter, Holdings Channel.com reports. The fund owned 1,385 shares of the medical research company’s stock after acquiring an additional 536 shares during the quarter. Blue Trust Inc.’s holdings in Bruker were worth $57,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Pinnacle Bancorp Inc. bought a new stake in Bruker during the 1st quarter valued at $29,000. Allworth Financial LP grew its stake in Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after buying an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Bruker by 1,354.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock worth $33,000 after buying an additional 745 shares during the last quarter. Parallel Advisors LLC grew its stake in Bruker by 63.0% during the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after buying an additional 347 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new position in Bruker during the 1st quarter worth $42,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BRKR. Jefferies Financial Group set a $60.00 price target on Bruker and gave the company a “buy” rating in a research note on Monday, August 4th. Stifel Nicolaus set a $40.00 target price on Bruker and gave the stock a “hold” rating in a research note on Tuesday, August 5th. Barclays lowered their target price on Bruker from $43.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, October 2nd. Citigroup lowered their target price on Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research note on Monday, August 4th. Finally, Bank of America lowered their target price on Bruker from $61.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, June 26th. Five analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $51.00.

Insider Activity at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the sale, the director owned 18,016 shares in the company, valued at approximately $581,016. The trade was a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 27.30% of the company’s stock.

Bruker Price Performance

BRKR stock opened at $36.98 on Friday. The business has a fifty day moving average of $33.48 and a two-hundred day moving average of $36.98. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The stock has a market cap of $5.61 billion, a price-to-earnings ratio of 71.12, a price-to-earnings-growth ratio of 5.18 and a beta of 1.20. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $64.64.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The firm had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.52 earnings per share. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, research analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd were given a dividend of $0.05 per share. The ex-dividend date was Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Bruker’s payout ratio is 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.